Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2008

01-03-2008

Immune cells as mediators of solid tumor metastasis

Authors: David G. DeNardo, Magnus Johansson, Lisa M. Coussens

Published in: Cancer and Metastasis Reviews | Issue 1/2008

Login to get access

Abstract

Outgrowths of disseminated metastases remain the primary cause of mortality in cancer patients; however, molecular and cellular mechanisms regulating metastatic spread remain largely elusive. Recent insights into these mechanisms have refined the seed and soil hypothesis and it is now recognized that metastasis of solid tumors requires collaborative interactions between malignant cells and a diverse assortment of “activated” stromal cells at both primary and secondary tumor locations. Specifically, persistent pro-tumor immune responses (inflammation), now generally accepted as potentiating primary tumor development, are also being recognized as mediators of cancer metastasis. Thus, novel anti-cancer therapeutic strategies targeting molecular and/or cellular mechanisms regulating these collaborative interactions may provide efficacious relief for metastatic disease. This review focuses on recent literature revealing new mechanisms whereby immune cells regulate metastatic progression, with a primary focus on breast cancer.
Literature
1.
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007). Cancer statistics. CA A Cancer Journal for Clinicians, 57, 43–66 2007.PubMedCrossRef
2.
Paget, S. (1889). The distribution of secondary growths in cancer of the breast. Lancet, 1, 571–573.CrossRef
3.
Karin, M., & Greten, F. R. (2005). NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nature Reviews. Immunology, 5, 749–759.PubMedCrossRef
4.
Coussens, L. M., & Werb, Z. (2001). Inflammatory cells and cancer: Think different!. Journal of Experimental Medicine, 193, F23–F26.PubMedCrossRef
5.
6.
7.
Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: Back to Virchow? Lancet, 357, 539–545.PubMedCrossRef
8.
Balkwill, F., Charles, K. A., & Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7, 211–217.PubMedCrossRef
9.
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer, 6, 24–37.PubMedCrossRef
10.
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nature Reviews. Cancer, 3, 453–458.PubMedCrossRef
11.
Chambers, A. F., Naumov, G. N., Varghese, H. J., Nadkarni, K. V., MacDonald, I. C., & Groom, A. C. (2001). Critical steps in hematogenous metastasis: An overview. Surgical Oncology Clinics of North America, 10, 243–255 vii.PubMed
12.
Folkman, J. (1992). The role of angiogenesis in tumor growth. Seminars in Cancer Biology, 3, 65–71.PubMed
13.
Woodhouse, E. C., Chuaqui, R. F., & Liotta, L. A. (1997). General mechanisms of metastasis. Cancer, 80, 1529–1537.PubMedCrossRef
14.
15.
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410, 50–56.PubMedCrossRef
16.
Wilson, J., & Balkwill, F. (2002). The role of cytokines in the epithelial cancer microenvironment. Seminars in Cancer Biology, 12, 113–120.PubMedCrossRef
17.
Borsig, L., Wong, R., Hynes, R. O., Varki, N. M., & Varki, A. (2002). Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proceedings of the National Academy of Sciences of the United States of America, 99, 2193–2198.PubMedCrossRef
18.
Laakkonen, P., Porkka, K., Hoffman, J. A., & Ruoslahti, E. (2002). A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nature Medicine, 8, 751–755.
19.
Karin, M., Lawrence, T., & Nizet, V. (2006). Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell, 124, 823–835.PubMedCrossRef
20.
Wu, J., & Lanier, L. L. (2003). Natural killer cells and cancer. Advances in Cancer Research, 90, 127–156.PubMed
21.
Theoharides, T. C., & Conti, P. (2004). Mast cells: The Jekyll and Hyde of tumor growth. Trends in Immunology, 25, 235–241.PubMedCrossRef
22.
Condeelis, J., & Pollard, J. W. (2006). Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell, 124, 263–266.PubMedCrossRef
23.
Mantovani, A., Allavena, P., & Sica, A. (2004). Tumour-associated macrophages as a prototypic type II polarised phagocyte population: Role in tumour progression. European Journal of Cancer, 40, 1660–1667.PubMedCrossRef
24.
Goswami, S., Sahai, E., Wyckoff, J. B., Cammer, M., Cox, D., Pixley, F. J., et al. (2005). Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Research, 65, 5278–5283.PubMedCrossRef
25.
Wyckoff, J., Wang, W., Lin, E. Y., Wang, Y., Pixley, F., Stanley, E. R., et al. (2004). A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Research, 64, 7022–7029.PubMedCrossRef
26.
Bergers, G., & Benjamin, L. E. (2003). Angiogenesis: Tumorigenesis and the angiogenic switch. Nature Reviews. Cancer, 3, 401–410.PubMedCrossRef
27.
Wyckoff, J. B., Wang, Y., Lin, E. Y., Li, J. F., Goswami, S., Stanley, E. R., et al. (2007). Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Research, 67, 2649–2656.PubMedCrossRef
28.
Lee, T. H., Seng, S., Sekine, M., Hinton, C., Fu, Y., Avraham, H. K., et al. (2007). Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Medicine, 4, e186.PubMedCrossRef
29.
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2, 737–744.PubMedCrossRef
30.
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & Development, 13, 1382–1397.
31.
Lin, E. Y., & Pollard, J. W. (2007). Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Research, 67, 5064–5066.PubMedCrossRef
32.
Robinson-Smith, T. M., Isaacsohn, I., Mercer, C. A., Zhou, M., Van Rooijen, N., Husseinzadeh, N., et al. (2007). Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Research, 67, 5708–5716.PubMedCrossRef
33.
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Molecular and Cellular Biology, 12, 954–961.PubMed
34.
Lin, E. Y., Gouon-Evans, V., Nguyen, A. V., & Pollard, J. W. (2002). The macrophage growth factor CSF-1 in mammary gland development and tumor progression. Journal of Mammary Gland Biology and Neoplasia, 7, 147–162.PubMedCrossRef
35.
Lin, E. Y., Li, J. F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., et al. (2006). Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Research, 66, 11238–11246.PubMedCrossRef
36.
O’Sullivan, C., & Lewis, C. E. (1994). Tumour-associated leucocytes: Friends or foes in breast carcinoma. Journal of Pathology, 172, 229–235.PubMedCrossRef
37.
Leek, R. D., & Harris, A. L. (2002). Tumor-associated macrophages in breast cancer. Journal of Mammary Gland Biology and Neoplasia, 7, 177–189.PubMedCrossRef
38.
Bolat, F., Kayaselcuk, F., Nursal, T. Z., Yagmurdur, M. C., Bal, N., & Demirhan, B. (2006). Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: Correlations with prognostic parameters. Journal of Experimental & Clinical Cancer Research, 25, 365–372.
39.
Tsutsui, S., Yasuda, K., Suzuki, K., Tahara, K., Higashi, H., & Era, S. (2005). Macrophage infiltration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density. Oncology Reports, 14, 425–431.PubMed
40.
Ohno, S., Ohno, Y., Suzuki, N., Kamei, T., Koike, K., Inagawa, H., et al. (2004). Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Research, 24, 3335–3342.PubMed
41.
Oosterling, S. J., van der Bij, G. J., Meijer, G. A., Tuk, C. W., van Garderen, E., van Rooijen, N., et al. (2005). Macrophages direct tumour histology and clinical outcome in a colon cancer model. Journal of Pathology, 207, 147–155.PubMedCrossRef
42.
Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481–490.PubMedCrossRef
43.
Ribatti, D., Crivellato, E., Roccaro, A. M., Ria, R., & Vacca, A. (2004). Mast cell contribution to angiogenesis related to tumour progression. Clinical & Experimental Allergy, 34, 1660–1664.CrossRef
44.
Ribatti, D., Vacca, A., Nico, B., Crivellato, E., Roncali, L., & Dammacco, F. (2001). The role of mast cells in tumour angiogenesis. British Journal of Haematology, 115, 514–521.PubMedCrossRef
45.
Benelli, R., Albini, A., & Noonan, D. (2003). Neutrophils and angiogenesis: Potential initiators of the angiogenic cascade. Chemical Immunology and Allergy, 83, 167–181.PubMed
46.
Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand-Rosenberg, S. (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Research, 67, 4507–4513.PubMedCrossRef
47.
De Palma, M., Venneri, M. A., Galli, R., Sergi Sergi, L., Politi, L. S., Sampaolesi, M., et al. (2005). Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell, 8, 211–226.PubMedCrossRef
48.
Bunt, S. K., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2006). Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. Journal of Immunology, 176, 284–290.
49.
Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews. Cancer, 2, 161–174.PubMedCrossRef
50.
Mueller, M. M., & Fusenig, N. E. (2004). Friends or foes—Bipolar effects of the tumour stroma in cancer. Nature Reviews. Cancer, 4, 839–849.PubMedCrossRef
51.
Joyce, J. A., & Hanahan, D. (2004). Multiple roles for cysteine cathepsins in cancer. Cell Cycle, 3, 1516–1619.PubMed
52.
Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G., & Quaranta, V. (1997). Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science, 277, 225–228.PubMedCrossRef
53.
Pirila, E., Ramamurthy, N. S., Sorsa, T., Salo, T., Hietanen, J., & Maisi, P. (2003). Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis). Digestive Diseases and Sciences, 48, 93–98.PubMedCrossRef
54.
Kalluri, R. (2003). Basement membranes: Structure, assembly and role in tumour angiogenesis. Nature Reviews. Cancer, 3, 422–433.PubMedCrossRef
55.
van Kempen, L. C., de Visser, K. E., & Coussens, L. M. (2006). Inflammation, proteases and cancer. European Journal of Cancer, 42, 728–734.PubMedCrossRef
56.
Cheng, K., Xie, G., & Raufman, J. P. (2007). Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochemical Pharmacology, 73, 1001–1012.PubMedCrossRef
57.
Wang, F., Sloss, C., Zhang, X., Lee, S. W., & Cusack, J. C. (2007). Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Research, 67, 8486–8493.PubMedCrossRef
58.
Gocheva, V., Zeng, W., Ke, D., Klimstra, D., Reinheckel, T., Peters, C., et al. (2006). Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes & Development, 20, 543–556.CrossRef
59.
Vasiljeva, O., Papazoglou, A., Kruger, A., Brodoefel, H., Korovin, M., Deussing, J., et al. (2006). Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Research, 66, 5242–5250.PubMedCrossRef
60.
Lin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J., et al. (2003). Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. American Journal of Pathology, 163, 2113–2126.PubMed
61.
Hagemann, T., Wilson, J., Kulbe, H., Li, N. F., Leinster, D. A., Charles, K., et al. (2005). Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. Journal of Immunology, 175, 1197–1205.
62.
Scott, K. A., Arnott, C. H., Robinson, S. C., Moore, R. J., Thompson, R. G., Marshall, J. F., et al. (2004). TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene, 23, 6954–6966.PubMedCrossRef
63.
Szlosarek, P. W., Grimshaw, M. J., Kulbe, H., Wilson, J. L., Wilbanks, G. D., Burke, F., et al. (2006). Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Molecular Cancer Therapeutics, 5, 382–390.PubMedCrossRef
64.
Szlosarek, P., Charles, K. A., & Balkwill, F. R. (2006). Tumour necrosis factor-alpha as a tumour promoter. European Journal of Cancer, 42, 745–750.PubMedCrossRef
65.
Luo, J. L., Tan, W., Ricono, J. M., Korchynskyi, O., Zhang, M., Gonias, S. L., et al. (2007). Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature, 446, 690–694.PubMedCrossRef
66.
Abraham, S., Zhang, W., Greenberg, N., & Zhang, M. (2003). Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. Journal of Urology, 169, 1157–1161.PubMedCrossRef
67.
Sager, R., Sheng, S., Pemberton, P., & Hendrix, M. J. (1997). Maspin. A tumor suppressing serpin. Advances in Experimental Medicine and Biology, 425, 77–88.PubMed
68.
Chen, E. I., & Yates, J. R. (2006). Maspin and tumor metastasis. IUMB Life, 58, 25–29.CrossRef
69.
Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., et al. (2006). Regulation of cancer cell migration and bone metastasis by RANKL. Nature, 440, 692–696.PubMedCrossRef
70.
Shi, H. Y., Zhang, W., Liang, R., Kittrell, F., Templeton, N. S., Medina, D., et al. (2003). Modeling human breast cancer metastasis in mice: Maspin as a paradigm. Histology and Histopathology, 18, 201–206.PubMed
71.
Lockett, J., Yin, S., Li, X., Meng, Y., & Sheng, S. (2006). Tumor suppressive maspin and epithelial homeostasis. Journal of Cellular Biochemistry, 97, 651–660.PubMedCrossRef
72.
Gorden, D. L., Fingleton, B., Crawford, H. C., Jansen, D. E., Lepage, M., & Matrisian, L. M. (2007). Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. International Journal of Cancer, 121, 495–500.CrossRef
73.
Lynch, C. C., Hikosaka, A., Acuff, H. B., Martin, M. D., Kawai, N., Singh, R. K., et al. (2005). MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell, 7, 485–496.PubMedCrossRef
74.
Lewis, C. E., & Pollard, J. W. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Research, 66, 605–612.PubMedCrossRef
75.
Leek, R. D., Hunt, N. C., Landers, R. J., Lewis, C. E., Royds, J. A., & Harris, A. L. (2000). Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. Journal of Pathology, 190, 430–436.PubMedCrossRef
76.
Wyckoff, J. B., Segall, J. E., & Condeelis, J. S. (2000). The collection of the motile population of cells from a living tumor. Cancer Research, 60, 5401–5404.PubMed
77.
Wang, W., Wyckoff, J. B., Goswami, S., Wang, Y., Sidani, M., Segall, J. E., et al. (2007). Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. Cancer Research, 67, 3505–3511.PubMedCrossRef
78.
Condeelis, J., & Segall, J. E. (2003). Intravital imaging of cell movement in tumours. Nature Reviews. Cancer, 3, 921–930.PubMedCrossRef
79.
Luzzi, K. J., MacDonald, I. C., Schmidt, E. E., Kerkvliet, N., Morris, V. L., Chambers, A. F., et al. (1998). Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. American Journal of Pathology, 153, 865–873.PubMed
80.
Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., et al. (2002). MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell, 2, 289–300.PubMedCrossRef
81.
Acuff, H. B., Carter, K. J., Fingleton, B., Gorden, D. L., & Matrisian, L. M. (2006). Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Research, 66, 259–266.PubMedCrossRef
82.
Hiratsuka, S., Watanabe, A., Aburatani, H., & Maru, Y. (2006). Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biology, 8, 1369–1375.PubMedCrossRef
83.
Lin, E. Y., & Pollard, J. W. (2004). Macrophages: Modulators of breast cancer progression. Novartis Foundation Symposium, 256, 158–168 discussion 68–72, 259–69.PubMed
84.
Kaplan, R. N., Psaila, B., & Lyden, D. (2006). Bone marrow cells in the ‘pre-metastatic niche’: Within bone and beyond. Cancer and Metastasis Reviews, 25, 521–529.PubMedCrossRef
85.
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438, 820–827.PubMedCrossRef
86.
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002). Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science, 295, 2387–2392.PubMedCrossRef
87.
Psaty, B. M., & Furberg, C. D. (2005). COX-2 inhibitors—Lessons in drug safety. New England Journal of Medicine, 352, 1133–1135.PubMedCrossRef
Metadata
Title
Immune cells as mediators of solid tumor metastasis
Authors
David G. DeNardo
Magnus Johansson
Lisa M. Coussens
Publication date
01-03-2008
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-007-9100-0

Other articles of this Issue 1/2008

Cancer and Metastasis Reviews 1/2008 Go to the issue

EditorialNotes

Tumor microenvironment, a dangerous society leading to cancer metastasis. From mechanisms to therapy and prevention

NON-THEMATIC REVIEW

Osteopontin: regulation in tumor metastasis

OriginalPaper

Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells

Acknowledgments

Bio

OriginalPaper

The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2

OriginalPaper

Metastasis signatures: genes regulating tumor–microenvironment interactions predict metastatic behavior
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits